Regenerative cell therapy biotech uses IPO to blast into human trials

Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

By Amy Baxter • June 5, 2024

Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges

By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.

By Alexandra Pecci • May 30, 2024

Traditional gene therapies are uber-niche. Ocugen hopes to change that.

The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.

By Alexandra Pecci • April 15, 2024

What’s old is new: The revival of a one-time radiotherapy cancer treatment

TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.

By Amy Baxter • April 10, 2024

GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

By Alexandra Pecci • March 19, 2024

Black Diamond looks to outwit cancer mutations

Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.

By Kelly Bilodeau • March 4, 2024

Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

By Alexandra Pecci • Feb. 6, 2024

One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery

4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.

By Michael Gibney • Jan. 10, 2024

This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

By Michael Gibney • Dec. 19, 2023

A biotech tackles drug discovery with transcription factor know-how

Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

By Michael Gibney • Nov. 15, 2023

A new delivery method muscling its way into the RNA space

With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

By Kelly Bilodeau • Nov. 8, 2023

Cidara’s J&J-partnered immunotherapy could target flu and cancer

On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

By Alexandra Pecci • Oct. 26, 2023

An ‘inverse vaccine’ takes aim at autoimmune diseases

Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

By Kelly Bilodeau • Oct. 23, 2023

To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

A biotech ‘tuning’ the genome for a potentially safer gene therapy

Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

By Kelly Bilodeau • Oct. 9, 2023

Immuneering takes aim at cancer’s ‘superhighway’

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

By Kelly Bilodeau • Sept. 11, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

Brii Biosciences aims to come up big where Sage and Biogen fell short

The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

By Kelly Bilodeau • Aug. 21, 2023

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

By Karissa Waddick • Aug. 7, 2023

How CymaBay overcame a NASH failure for another shot at liver disease success

The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

By Michael Gibney • Aug. 2, 2023

Zai Lab looks to expand beyond China and make a global impact in oncology

Focused on making a “transformational” impact, the company is developing targeted treatments driven by specific cancer mutations.

By Kelly Bilodeau • June 12, 2023

How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

By Taren Grom • May 5, 2023

Emalex aims at a first-in-class breakthrough for Tourette syndrome

With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

By Kelly Bilodeau • May 1, 2023

This biotech’s ‘Microsoft’ approach could change how we see gene therapy

The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.

By Karissa Waddick • March 20, 2023

Babson aims to shed Theranos curse with new blood testing tech

Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

By Kelly Bilodeau • March 13, 2023